Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.

Shemesh, Colby S; Chan, Phyllis; Shao, Hui; Xu, Derek-Zhen; Combs, Daniel; Vadhavkar, Shweta; Bruno, René; Wu, Benjamin

Shemesh, Colby S; Chan, Phyllis; Shao, Hui; Xu, Derek-Zhen; Combs, Daniel; Vadhavkar, Shweta; Bruno, René; Wu, Benjamin.

Afiliación

Shemesh CS; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.
Chan P; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.
Shao H; Safety Science, F. Hoffmann-La Roche Ltd., Beijing, China.
Xu DZ; Product Development Oncology, F. Hoffmann-La Roche Ltd., Shanghai, China.
Combs D; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.
Vadhavkar S; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.
Bruno R; Clinical Pharmacology, Genentech-Roche, Marseille, France.
Wu B; Department of Clinical Pharmacology, Genentech Inc., South San Francisco, California, USA.

Liver Cancer ; 10(5): 485-499, 2021 Sep.

Article en En | MEDLINE | ID: mdl-34721510

Palabras clave

Atezolizumab; Bevacizumab; Clinical pharmacology; Geographic region; Hepatic impairment

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Liver Cancer Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google